Cancer Research on Prevention and Treatment    2021, Vol. 48 Issue (11) : 1046-1052     DOI: 10.3971/j.issn.1000-8578.2021.21.0508
Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy
SUN Chongyuan, ZHAO Dongbing
Department of Pancreatic and Gastric Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Download: PDF(2790 KB)   ( 42 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Despite the continuous development of medical devices and the standardization of gastrectomy plus D2 lymph node dissection, advanced gastric cancer still has high distant metastasis rate and local recurrence rate, and the prognosis is poor. Neoadjuvant chemotherapy can improve the long-term survival of patients with advanced gastric cancer by reducing tumor stage, increasing R0 resection rate and eliminating potential micrometastasis. However, it is still the focus of concern that whether the adverse reactions of preoperative chemotherapy will increase the incidence of postoperative complications. Postoperative complications can affect the oncological outcomes by activating minimal residual lesions and promoting metastasis through related inflammatory changes or delaying adjuvant therapy, so the premise of wide application of neoadjuvant chemotherapy should be the guarantee of surgical safety. This article reviews the incidence, severity and prognosis of operative complications in gastric cancer patients after neoadjuvant chemotherapy and further explores its influencing factors.
Keywords Gastric cancer      Neoadjuvant chemotherapy      Operative complication      Risk factors     
ZTFLH:  R735.2  
Issue Date: 12 November 2021
 Cite this article:   
SUN Chongyuan,ZHAO Dongbing. Characteristics and Risk Factors of Postoperative Complications in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1046-1052.
E-mail this article
E-mail Alert
Articles by authors
SUN Chongyuan
ZHAO Dongbing

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and Mortality Worldwide
for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,
71(3): 209-249.

[2] Thrift AP, El-Serag HB. Burden of Gastric Cancer[J]. Clin
Gastroenterol Hepatol, 2020, 18(3): 534-542.
[3] Nie Y, Wu K, Yu J, et al. A global burden of gastric cancer: the
major impact of China[J]. Expert Rev Gastroenterol Hepatol,
2017, 11(7): 651-661.
[4] Allemani C, Weir HK, Carreira H, et al. Global surveillance
of cancer survival 1995–2009: analysis of individual data for
25 676 887 patients from 279 population-based registries in 67
countries (CONCORD-2)[J]. Lancet, 2015, 385(9972): 977-1010.
[5] Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy
in locally advanced and nonresectable gastric cancer: a phase
II study with etoposide, doxorubicin, and cisplatin[J]. J Clin
Oncol,1989,7(9): 1318-1326.
[6] Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant
chemotherapy compared with surgery alone for locally advanced
cancer of the stomach and cardia: European Organisation for
Research and Treatment of Cancer randomized trial 40954[J]. J
Clin Oncol, 2010,28(35): 5210-5218.
[7] Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy
compared with surgery alone for resectable gastroesophageal
adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ
trial[J]. J Clin Oncol, 2011, 29(13): 1715-1721.
[8] Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological
regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil,
and leucovorin versus epirubicin, cisplatin, and fluorouracil
or capecitabine in patients with resectable gastric or gastrooesophageal
junction adenocarcinoma (FLOT4-AIO): results from
the phase 2 part of a multicentre, open-label, randomised phase
2/3 trial[J]. Lancet Oncol, 2016, 17(12): 1697-708.
[9] Al-Batran SE, Homann N, Pauligk C, et al. Perioperative
chemotherapy with fluorouracil plus leucovorin, oxaliplatin,
and docetaxel versus fluorouracil or capecitabine plus cisplatin
and epirubicin for locally advanced, resectable gastric or gastrooesophageal
junction adenocarcinoma (FLOT4): a randomised,
phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957.
[10] Yu Y, Fang Y, Shen Z, et al. Oxaliplatin plus Capecitabine
in the Perioperative Treatment of Locally Advanced Gastric
Adenocarcinoma in Combination with D2 Gastrectomy: NEOCLASSIC
Study[J]. Oncologist, 2019, 24(10): 1311-e989.
[11] Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical
Oncology (CSCO): clinical guidelines for the diagnosis and
treatment of gastric cancer[J]. Cancer Commun (Lond), 2019,
39(1): 10.
[12] Kurita N, Miyata H, Gotoh M, et al. Risk Model for Distal
Gastrectomy When Treating Gastric Cancer on the Basis of Data
From 33,917 Japanese Patients Collected Using a Nationwide
Web-based Data Entry System[J]. Ann Surg, 2015, 262(2):
[13] Wang JB, Que SJ, Chen QY, et al. Prognostic analysis of patients
with intra-abdominal infectious complications after laparoscopicassisted
and open radical gastrectomy for gastric cancer - A
propensity score-matching analysis[J]. Surg Oncol, 2021, 37:
[14] Obana A, Koyama M, Suwa T, et al. Impact of Postoperative
Complications on Gastric Cancer Survival and Recurrence[J]. J
Am Coll Surg, 2019, 229(4, Supplement 1): S265.
[15] Han WH, Oh YJ, Eom BW, et al. Prognostic impact of infectious
complications after curative gastric cancer surgery[J]. Eur J Surg
Oncol, 2020, 46(7): 1233-1238.
[16] Li SS, Udelsman BV, Parikh A, et al. Impact of Postoperative
Complication and Completion of Multimodality Therapy on
Survival in Patients Undergoing Gastrectomy for Advanced
Gastric Cancer[J]. J Am Coll Surg, 2020, 230(6): 912-924.
[17] Vicente D, Ikoma N, Chiang YJ, et al. Preoperative Therapy
for Gastric Adenocarcinoma is Protective for Poor Oncologic
Outcomes in Patients with Complications After Gastrectomy[J].
Ann Surg Oncol, 2018, 25(9): 2720-2730.
[18] Li J, Zhang Y, Hu DM, et al. Impact of postoperative
complications on long-term outcomes of patients following
surgery for gastric cancer: A systematic review and meta-analysis
of 64 follow-up studies[J]. Asian J Surg, 2020, 43(7): 719-29.
[19] Gowing SD, Cool-Lartigue JJ, Spicer JD, et al. Toll-like receptors:
exploring their potential connection with post-operative infectious
complications and cancer recurrence[J]. Clin Exp Metastasis,
2020, 37(2): 225-239.
[20] Kubota T, Hiki N, Sano T, et al. Prognostic significance of
complications after curative surgery for gastric cancer[J]. Ann
Surg Oncol, 2014, 21(3): 891-898.
[21] Kim MR, Kim AS, Choi HI, et al. Inflammatory markers for
predicting overall survival in gastric cancer patients: A systematic
review and meta-analysis[J]. PLoS One, 2020, 15(7): e0236445.
[22] Wu L, Ge L, Qin Y, et al. Postoperative morbidity and mortality
after neoadjuvant chemotherapy versus upfront surgery for locally
advanced gastric cancer: a propensity score matching analysis[J].
Cancer Manag Res, 2019, 11: 6011-6018.
[23] Yan Y, Yang A, Lu L, et al. Impact of Neoadjuvant Therapy on
Minimally Invasive Surgical Outcomes in Advanced Gastric
Cancer: An International Propensity Score-Matched Study[J].Ann
Surg Oncol, 2021, 28(3): 1428-1436.
[24] Charruf AZ, Ramos MFKP, Pereira MA, et al. Impact of
neoadjuvant chemotherapy on surgical and pathological results
of gastric cancer patients: A case-control study[J]. J Surg Oncol,
2020, 121(5): 833-839.
[25] Coccolini F, Nardi M, Montori G, et al. Neoadjuvant
chemotherapy in advanced gastric and esophago-gastric cancer.
Meta-analysis of randomized trials[J]. Int J Surg, 2018, 51: 120-7.
[26] Téoule P, Trojan J, Bechstein W, et al. Impact of Neoadjuvant
Chemotherapy on Postoperative Morbidity after Gastrectomy for
Gastric Cancer[J]. Dig Surg, 2015, 32(4): 229-237.
[27] Wei Z, Tan B, Cao S, et al. The influence of neoadjuvant
chemotherapy on gastric cancer patients’ postoperative infectious
complications: What is the negative role played by the intestinalbarrier dysfunction?[J]. Oncotarget, 2017, 8(26): 43376-43388.
[28] Ganschow P, Hofmann L, Stintzing S, et al. Operative Results
and Perioperative Morbidity After Intensified Neoadjuvant
Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma
Impact of Intensified Neoadjuvant Treatment[J]. J Gastrointest
Surg, 2021, 25(1): 58-66.
[29] Eto K, Hiki N, Kumagai K, et al. Prophylactic effect of
neoadjuvant chemotherapy in gastric cancer patients with
postoperative complications[J]. Gastric Cancer, 2018, 21(4):
[30] Hayashi M, Yoshikawa T, Yura M, et al. Does neoadjuvant
chemotherapy cancel out the negative survival impact induced
by surgical complications after gastrectomy?[J]. Gastric Cancer,
2019, 22(6): 1274-1284.
[31] Hayashi M, Yoshikawa T, Yura M, et al. Intraoperative blood loss
as an independent prognostic factor for curative resection after
neoadjuvant chemotherapy for gastric cancer: a single-center
retrospective cohort study[J]. Surg Today, 2021, 51(2): 293-302.
[32] Hayashi T, Aoyama T, Tanabe K, et al. Low creatinine
clearance is a risk factor for D2 gastrectomy after neoadjuvant
chemotherapy[J]. Ann Surg Oncol, 2014, 21(9): 3015-3022.
[33] 崔昊, 张珂诚, 曹博, 等. 进展期胃癌新辅助化疗患者全胃切
除术后并发症影响因素分析[J]. 中华胃肠外科杂志, 2021,
24(2): 153-159. [Cui H, Zhang K C, Cao B, et al. Risk factors of
postoperative complication after total gastrectomy in advanced
gastric cancer patients receiving neoadjuvant chemotherapy[J].
Zhonghua Wei Chang Wai Ke Za Zhi, 2021, 24(2): 153-159.
[34] Dias AR, Pereira MA, Oliveira RJ, et al. Multivisceral resection
vs standard gastrectomy for gastric adenocarcinoma[J]. J Surg
Oncol, 2020, 121(5): 840-847.
[35] Ahn HS, Jeong SH, Son YG, et al. Effect of neoadjuvant
chemotherapy on postoperative morbidity and mortality in
patients with locally advanced gastric cancer[J]. Br J Surg, 2014,
101(12): 1560-1565.
[36] Molina JC, Al-Hinai A, Gosseling-Tardif A, et al. Multivisceral
Resection for Locally Advanced Gastric and Gastroesophageal
Junction Cancers-11-Year Experience at a High-Volume North
American Center[J]. J Gastrointest Surg, 2019, 23(1): 43-50.
[37] Claassen YHM, Hartgrink HH, Dikken JL, et al. Surgical
morbidity and mortality after neoadjuvant chemotherapy in the
CRITICS gastric cancer trial[J]. Eur J Surg Oncol, 2018, 44(5):
[38] Tan BH, Brammer K, Randhawa N, et al. Sarcopenia is associated
with toxicity in patients undergoing neo-adjuvant chemotherapy
for oesophago-gastric cancer[J]. Eur J Surg Oncol, 2015, 41(3):
[39] Matsuura N, Motoori M, Fujitani K, et al. Correlation between
Skeletal Muscle Mass and Adverse Events of Neoadjuvant
Chemotherapy in Patients with Gastric Cancer[J]. Oncology,
2020, 98(1): 29-34.
[40] Mirkin KA, Luke FE, Gangi A, et al. Sarcopenia related to
neoadjuvant chemotherapy and perioperative outcomes in resected
gastric cancer: a multi-institutional analysis[J]. J Gastrointest
Oncol, 2017, 8(3): 589-595.
[41] Zhang Y, Li Z, Jiang L, et al. Impact of body composition on
clinical outcomes in people with gastric cancer undergoing radical
gastrectomy after neoadjuvant treatment[J]. Nutrition, 2021, 85:
[42] Reim D, Hüser N, Humberg D, et al. Preoperative clinically
inapparent leucopenia in patients undergoing neoadjuvant
chemotherapy for locally advanced gastric cancer is not a risk
factor for surgical or general postoperative complications[J]. J
Surg Oncol, 2010, 102(4): 321-324.


Related articles from Frontiers Journals
[1] WANG Yue, ZHAO Weizhe, LI Xiaojie, NAN Mengdie, XIE Meiwen, LI Peijin, HOU Li. Traditional Chinese Medicine Combined with Chemotherapy in Prevention and Treatment of Recurrence and Metastasis of Locally Advanced Gastric Cancer After Radical Resection: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 913-922.
[2] MAO Wanli, RAN Li, LI Jiehui, LI Fenghu, CHANG Jianying, MU Junyu, MEI Fan, HU Lili, DU Yanjun, TIAN Xue, QIN Yao, YIN Shuishui. Predictive Value of CD44v6 and EGFR Expression in Neoadjuvant Chemotherapy Sensitivity of Stage Ⅱ-Ⅲ Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 937-943.
[3] TANG Wenhao. Negative Feedback Mechanism of Entero-gastric Inhibitory in Delayed Gastric Emptying Following Surgery for Stomach Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 760-763.
[4] JIA Lijuan, ZHANG Yunqiang, ZHANG Baihong, YUE Hongyun. Expression and Clinical Significance of m6A Methylatransferase ZC3H13 in Gastric Cancer Tissues and Serum[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 792-798.
[5] WANG Daorong, WANG Wei. History and Current Situation of Digestive Tract Reconstruction After Laparoscopic Proximal Radical Gastrectomy[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 644-648.
[6] ZHANG Rui, PENG Tao, YIN Jian, SONG Song, WANG Shen, MI Zihan, CHEN Wen, REN Jiansong. Expression and Significance of Serum DKK1 in Gastric Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 692-697.
[7] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[8] LU Shunli, YU Jianping, CHEN Weikai, LI Andong, HE Qingyuan, CHEN Chao, HAN Xiaopeng. Research Progress of Genes Related to Treatment and Prognosis of Alpha-fetoprotein Producing Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 738-744.
[9] TANG Yinbing, ZHANG Heteng, ZHANG Wenbo, JIANG Pengcheng. Research Progress on Roles of lncRNA as ceRNA in EMT of Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(04): 352-358.
[10] YANG Huan, SUN Wanyi, WANG Jianbing, WANG Xiaokun, ZHANG Jinyu, FAN Jinhu, QIAO Youlin. Research Progress of Etiology, Screening and Early Diagnosis of Esophageal Cancer in China[J]. Cancer Research on Prevention and Treatment, 2022, 49(03): 169-175.
[11] ZHANG Qiao, HUANG Changzhi, ZHU Jianjiang, LI Yan, ZHAO Mei, LI Kexin, LI Dongdong, QI Hong, HUANG Shengkai. Effect of NAIF1 on IFIT Family Proteins in Gastric Cance[J]. Cancer Research on Prevention and Treatment, 2022, 49(02): 90-94.
[12] QIAO Yihuan, LI Jipeng, CHEN Le, DU Zhenghua, GUO Yuan. Risk Factors of Vascular Invasion in Patients with Resectable Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(02): 123-127.
[13] WANG Yuanyuan, LYU Xiaohong. MiR-218-5p Promotes Rotenone-induced Apoptosis of Gastric Cancer Cells by Inhibiting TDP1 Expression[J]. Cancer Research on Prevention and Treatment, 2022, 49(01): 12-17.
[14] LU Mei, YANG Xiaojuan, ZOU Jieya, GUO Rong, WANG Xin, ZHANG Qian, DENG Xuepeng, TAO Jianfen, NIE Jianyun, YANG Zhuangqing. Efficacy Prediction Model for Neoadjuvant Chemotherapy on Breast Cancer Based on Differential Genes Expression[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1071-1077.
[15] ZHU Hao, JIA Jianchao, YU Lan. Research Progress on CircRNA in Liquid Biopsy of Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(11): 1023-1029.
Full text